期刊
ONCOTARGETS AND THERAPY
卷 14, 期 -, 页码 4061-4075出版社
DOVE MEDICAL PRESS LTD
DOI: 10.2147/OTT.S312249
关键词
multiple myeloma; chidamide; lenalidomide; reactive oxygen species
资金
- National Natural Science Foundation of China [81570117]
- Natural Science Foundation of Hunan Province [2018JJ2651]
- Medical Science Research Special Fund of Medical and Health Public Welfare Foundation of Beijing [YWJKJJH-KYJJ-B17464]
- Basic Ability Promotion Project in Middle-Aged
- National Natural Science Funds of China [81700125]
The combination therapy of chidamide and lenalidomide shows a synergistic effect in increasing ROS levels, inducing apoptosis, and inhibiting cell proliferation, thereby enhancing the treatment efficacy against multiple myeloma.
Background: Lenalidomide, an immunomodulatory drug (IMiD), is an effective therapy for the treatment of multiple myeloma (MM). However, prolonged treatment may be accompanied by toxicity, second primary malignancies, and drug resistance. There is an inherent vulnerability in MM cells that high rates of immunoglobulin synthesis resulting in the high level of reactive oxygen species (ROS). This provides a therapeutic potential for MM. Materials and Methods: The intracellular ROS levels, H2O2 production and glutathione (GSH) levels were measured using detection kit. Cell viability was evaluated using cell-counting kit-8 (CCK-8) and soft agar colony formation assay. Apoptosis was determined in whole living cells using flow cytometry. Chidamide and its anti-myeloma efficacy in combination with lenalidomide were characterized in MM cell lines in vitro and in a mouse xenograft model. Moreover, Western blotting, immunofluorescence and immunohistochemical studies were performed. Results: ROS levels increased in a time-and dose-dependent manner with chidamide treatment. Moreover, the GSH levels were decreased and the mRNA level of SLC7A11 downregulated after chidamide treatment. The co-treatment with chidamide and lenalidomide increased apoptosis and proliferation inhibition, with combination index (CI) in the synergistic range (0.2-0.5) using the Chou-Talalay method. The cooperative anti-myeloma efficacy was confirmed in the murine model, and immunohistochemical studies also supported this potentiation. Chidamide enhanced the effect of lenalidomide-induced degradation of IKZF1 and IKZF3 by elevating H2O2. In addition, co-treatment with chidamide and lenalidomide increased biomarkers of caspase and DNA damage. Conclusion: Elevated ROS production may constitute a potential biochemical basis for antimyeloma effects of chidamide plus lenalidomide. The results of this study confirm the synergistic effect of chidamide and lenalidomide against MM and provide a promising therapeutic strategy for MM.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据